Michael Richard Hodges
Highly experienced and successful PHARMA/Biotech industry veteran with BOD, Venture Capital/investment and NewCo start up expertise.
- Role
- Board Member at Telesis Bio
- Location
- San Diego, CA, US
- LinkedIn followers
- 500 followers
About Michael Richard Hodges
Michael R. Hodges, MD, MBBS, BSc, MRCPMichael is a highly experienced and successful pharmaceutical industry veteran. He has worked on multiple drug development programs in big PHARMA as the team leader/team member that have led to global regulatory approvals. Within biotech he has been part of teams that have raised Series B and C rounds of financing (~$150MM), F-1/IPO submission, reverse merger and successful M & As. He has deep disease-specific and RNA therapeutics drug development expertise. He is currently supporting a number of Biotechnology companies and VCs in the role of scientific advisor and/or board director. Michael is an entrepreneur in residence (EIR) at Claris Ventures a biotechnology venture capital fund based in Turin (Italy) with the mission to unlock the full potential of the Italian R&D ecosystem by establishing biotechnology NewCos founded on transformational IP from top Italian scientists and to develop/nurture the early stage Biotechs as they become established and grow. He was previously a partner at Claris for Fund 1. Also, he is a member of the science advisory boards of Adjuvant Capital, Arcturus, Cerberus, Memo and Ochre Therapeutics. He is a non-executive (NED) Director of Telesis Bio. He is also CEO of 1strand not-for-profit organization with the mission to promote R&D for San Diego County RNA therapeutics industry and to be a forum for continual education to highlight the positive impact of RNA medicines on public health.Michael was previously the CMO of Amplyx Pharmaceuticals, developing small molecule and monoclonal antibody drug treatments for life-threatening viral and fungal infections in immunocompromised patients. The company was acquired by Pfizer, Inc. Prior to Amplyx he was the CMO and head of drug development for Santaris A/S, developing RNA targeting drug treatments for viral, cancer, metabolic/lipid and eye diseases. The company was acquired by Hoffman-La Roche, AG. Michael started his career in pharmaceutical medicines with Pfizer Global Research and Development where he worked on multiple infectious diseases and oncology development programs. Under his leadership two antifungal drugs where approved, VFEND® (voriconazole) and ERAXIS™ (anidulafungin). Michael has been a NED for the following biotechnology companies: F2G Ltd. antifungal 2010-14; Hybridize Therapeutics Kidney targeting RNA 2021-24; AbVacc ID vaccines and monoclonal antibodies 2021-24. He earned his M.D.(MBBS) and BSc. in Pharmacology, from the University of London, UK.
Experience
Board Member
Jul 2024 — Present · San Diego, CA, US
Education
King's College London
Bachelor of Science - BS, Pharmacology
Westminster Medical School, University of London
MB BS, Medicine
1982 — 1985
Skills
- Drug Development
- Cancer
- Biopharmaceuticals
- Immunology
- Pharmaceutical Industry
- Regulatory Submissions
- Patents
- Oncology
- Infectious Diseases
- Clinical Trials
- Medicine
- Ind
- Translational Medicine
- Lifesciences
- Clinical Study Design
- Clinical Development
- Therapeutic Areas
- Pharmacology
- Life Sciences
- Biotechnology
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.